Literature DB >> 16372300

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance.

Diane Descamps1, Constance Delaugerre, Bernard Masquelier, Annick Ruffault, Anne-Geneviève Marcelin, Jacques Izopet, Marie-Laure Chaix, Vincent Calvez, Françoise Brun-Vézinet, Dominique Costagliola.   

Abstract

The performance of French virology laboratories belonging to the ANRS network has been assessed annually for 3 years. The performance of these laboratories was compared between the years 2002 and 2003. Ten and 7 coded samples were sent to 38 virology laboratories in 2002 and 45 virology laboratories in 2003, respectively. Each panel of coded samples included at least one HIV-negative control, a pair of duplicate specimens, samples with a wide range of viral loads, and samples with a large number of resistance mutations. The laboratories used their standard sequencing procedures and were asked to report the amino acids at codons associated with resistance mutations, based on the IAS-USA expert panel list. The reference amino acid sequences were defined as those most frequently reported by the participants. The specificity of detection of RT mutations was significantly better in 2003 (99.9%) than in 2002 (99.7%) (P = 0.05). There was no difference between 2002 and 2003 in the specificity of detection of protease mutations (99.6% and 99.8%) or the sensitivity of detection of RT mutations (98.8% and 98.2%). The sensitivity of detection of protease mutations improved significantly between 2002 and 2003 (97.6% and 99.0%, respectively; P = 0.037). The proportion of laboratories reporting fully accurate results, in terms of amplification, specificity, sensitivity, and reproducibility, tended to increase between 2002 and 2003 (P = 0.077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16372300     DOI: 10.1002/jmv.20522

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010.

Authors:  Neil Parkin; James Bremer; Silvia Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

Review 2.  Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Authors:  Robert W Shafer; Soo-Yon Rhee; Diane E Bennett
Journal:  Antivir Ther       Date:  2008

3.  Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.

Authors:  Sihong Xu; Jingyun Li; Zuoyi Bao; Hui Xing; Ping Zhong; Hanping Li; Haiwei Zhou; Xinping Li; Sharon Wu; Aijing Song; Xiuhua Li; Jianhui Nie; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

4.  Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Authors:  Eugène Messou; Marie-Laure Chaix; Delphine Gabillard; Albert Minga; Elena Losina; Vincent Yapo; Martial Kouakou; Christine Danel; Caroline Sloan; Christine Rouzioux; Kenneth A Freedberg; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

5.  HIV-1 Subtype distribution in morocco based on national sentinel surveillance data 2004-2005.

Authors:  Mohammed Akrim; Sanae Lemrabet; Elmir Elharti; Rebecca R Gray; Jean Claude Tardy; Robert L Cook; Marco Salemi; Patrice Andre; Taj Azarian; Rajae El Aouad
Journal:  AIDS Res Ther       Date:  2012-02-14       Impact factor: 2.250

6.  Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Authors:  Anne-Genevieve Marcelin; Philippe Flandre; Diane Descamps; Laurence Morand-Joubert; Charlotte Charpentier; Jacques Izopet; Mary-Anne Trabaud; Henia Saoudin; Constance Delaugerre; Catherine Tamalet; Jacqueline Cottalorda; Magali Bouvier-Alias; Dominique Bettinger; Georges Dos Santos; Annick Ruffault; Chakib Alloui; Cecile Henquell; Sylvie Rogez; Francis Barin; Anne Signori-Schmuck; Sophie Vallet; Bernard Masquelier; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

7.  Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

Authors:  Constance Delaugerre; Marie-Laure Chaix; Stephane Blanche; Josiane Warszawski; Dorine Cornet; Catherine Dollfus; Veronique Schneider; Marianne Burgard; Albert Faye; Laurent Mandelbrot; Roland Tubiana; Christine Rouzioux
Journal:  Retrovirology       Date:  2009-09-19       Impact factor: 4.602

8.  Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Authors:  Anne-Genevieve Marcelin; Bernard Masquelier; Diane Descamps; Jacques Izopet; Charlotte Charpentier; Chakib Alloui; Magali Bouvier-Alias; Anne Signori-Schmuck; Brigitte Montes; Marie-Laure Chaix; Corinne Amiel; Georges Dos Santos; Annick Ruffault; Francis Barin; Gilles Peytavin; Marc Lavignon; Philippe Flandre; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

9.  Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Authors:  Constance Delaugerre; Philippe Flandre; Marie Laure Chaix; Jade Ghosn; François Raffi; Pierre Dellamonica; H Jaeger; D Shürmann; Isabelle Cohen-Codar; Philippe Ngo Van; Michael Norton; Anne-Marie Taburet; Jean-François Delfraissy; Christine Rouzioux
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.

Authors:  Stéphanie Raymond; Florence Nicot; Coralie Pallier; Pantxika Bellecave; Anne Maillard; Mary Anne Trabaud; Laurence Morand-Joubert; Audrey Rodallec; Corinne Amiel; Thomas Mourez; Laurence Bocket; Agnès Beby-Defaux; Magali Bouvier-Alias; Sidonie Lambert-Niclot; Charlotte Charpentier; Brice Malve; Audrey Mirand; Julia Dina; Hélène Le Guillou-Guillemette; Stéphanie Marque-Juillet; Anne Signori-Schmuck; Francis Barin; Ali Si-Mohamed; Véronique Avettand Fenoel; Catherine Roussel; Vincent Calvez; Karine Saune; Anne Geneviève Marcelin; Christophe Rodriguez; Diane Descamps; Jacques Izopet
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.